Clinical Rheumatology

, Volume 25, Issue 5, pp 769–771

Infliximab in a child with therapy-resistant systemic vasculitis

  • Sandra W. K. de Kort
  • Marion A. J. van Rossum
  • Rebecca ten Cate
Case Report


Treatment of systemic vasculitides is usually based on the use of corticosteroids and other immunosuppressive drugs. We describe a 10-year-old girl with systemic vasculitis resistant to immunosuppressive treatment who had a rapid and impressive response to treatment with infliximab.


Childhood systemic vasculitis Infliximab Juvenile polyarteritis nodosa 


  1. 1.
    Petty RE, Cassidy JT (2000) Vasculitis and its classification. In: Cassidy JT and Petty RE (eds) Textbook of Pediatric Rheumatology. WB Saunders Company, pp 564–603Google Scholar
  2. 2.
    Ozen S, Besbas N, Saatci U, Bakkaloglu A (1992) Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 2:206–209Google Scholar
  3. 3.
    Ozen S (2002) The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 16:411–425PubMedGoogle Scholar
  4. 4.
    Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. (2004) Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 145:517–522CrossRefPubMedGoogle Scholar
  5. 5.
    Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L (2002) Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41:1126–1132CrossRefPubMedGoogle Scholar
  6. 6.
    Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe S, Probert L, et al. (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and lethality in vivo. Cytokine 7:15–25CrossRefPubMedGoogle Scholar
  7. 7.
    Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS (2001) De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 85:478–483CrossRefPubMedGoogle Scholar
  8. 8.
    Huong du L, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571–2576PubMedGoogle Scholar
  9. 9.
    Lipsky PE, Van Der Heijde DMFM, William St. Clair E, Furst DE, Breedveld FC, Kalden JR, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602CrossRefPubMedGoogle Scholar
  10. 10.
    Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn′s disease. Gastroenterology 117:761–769PubMedCrossRefGoogle Scholar
  11. 11.
    Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. (2004) Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717–721CrossRefPubMedGoogle Scholar
  12. 12.
    Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behçet’s disease. Arthritis Rheum 49:599–600CrossRefPubMedGoogle Scholar
  13. 13.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb B (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808–810PubMedGoogle Scholar
  14. 14.
    Lahdenne P, Vähäsalo, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247CrossRefPubMedGoogle Scholar
  15. 15.
    Antoni C, Braun J (2002) Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 20:s152–s157PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2005

Authors and Affiliations

  • Sandra W. K. de Kort
    • 1
  • Marion A. J. van Rossum
    • 2
  • Rebecca ten Cate
    • 3
  1. 1.Amphia HospitalBredaThe Netherlands
  2. 2.Emma Children’s Hospital AMCPaediatric RheumatologyAmsterdamThe Netherlands
  3. 3.Leiden University Medical CentreLeidenThe Netherlands

Personalised recommendations